PDCD1 and neoplasm: The anti-PD-1 antibody + chidamide (50 mg/kg) + celecoxib (50 mg/kg) regimen resulted in significant suppression of tumor growth, with primary tumor eradication in 7 out of 9 mice, and 88.9% survival at day 59 after tumor implantation (Fig. 2A,B,D).